Biomedical Development Corporation   Report issue

For profit Phase 1 Phase 2 Phase 3
Founded: Lexington KY United States (1984)
Status: No NME R&D (1984)

Organization Overview

First Clinical Trial
2006
NCT00566904
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2013

Timeline

NOW
  • Now

Active Ingredients

Drugs in Phase 3 Trials (1)

lactobacillus casei (1 trial)

Drugs in Phase 2 Trials (1)

iodine (2 trials)

Drugs in Phase 1 Trials (2)

acetylsalicylic acid (aspirin) (1 trial)

lidocaine (xylocaine) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Gingivitis (Phase 2)

Inflammation (Phase 2)

Neuralgia (Phase 1)

Neuralgia, Postherpetic (Phase 1)

Rhinitis (Phase 3)

Rhinitis, Allergic (Phase 3)

Rhinitis, Allergic, Perennial (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 4
  • # of Trial APIs: 4